Free Trial

Eli Lilly and Company (LLY) Stock Forecast & Price Target

Eli Lilly and Company logo
$844.30 -0.76 (-0.09%)
Closing price 10/7/2025 03:59 PM Eastern
Extended Trading
$847.14 +2.85 (+0.34%)
As of 06:33 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
10
Buy
15

Based on 25 Wall Street analysts who have issued ratings for Eli Lilly and Company in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 25 analysts, 10 have given a hold rating, 14 have given a buy rating, and 1 has given a strong buy rating for LLY.

Consensus Price Target

$938.94
11.21% Upside
According to the 25 analysts' twelve-month price targets for Eli Lilly and Company, the average price target is $938.94. The highest price target for LLY is $1,190.00, while the lowest price target for LLY is $700.00. The average price target represents a forecasted upside of 11.21% from the current price of $844.30.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for LLY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Eli Lilly and Company and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LLY Analyst Ratings Over Time

TypeCurrent Forecast
10/8/24 to 10/8/25
1 Month Ago
9/8/24 to 9/8/25
3 Months Ago
7/10/24 to 7/10/25
1 Year Ago
10/9/23 to 10/8/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
14 Buy rating(s)
14 Buy rating(s)
16 Buy rating(s)
16 Buy rating(s)
Hold
10 Hold rating(s)
8 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$938.94$950.17$1,011.61$977.35
Forecasted Upside11.21% Upside28.65% Upside28.02% Upside6.96% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

LLY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

LLY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Eli Lilly and Company Stock vs. The Competition

TypeEli Lilly and CompanyMedical CompaniesS&P 500
Consensus Rating Score
2.64
2.33
2.51
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside11.21% Upside1,308.16% Upside170.14% Upside
News Sentiment Rating
Positive News

See Recent LLY News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/3/2025Morgan Stanley
3 of 5 stars
Terence Flynn
Terence Flynn
Not Rated
Lower TargetOverweight$1,028.00 ➝ $1,023.00+24.65%
10/1/2025HSBC
2 of 5 stars
Rajesh Kumar
Rajesh Kumar
Not Rated
Boost Target$700.00 ➝ $800.00-4.81%
9/27/2025Weiss Ratings
0 of 5 stars
 Reiterated RatingHold (C+)
9/17/2025Berenberg Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuyHold$970.00 ➝ $830.00+8.70%
9/16/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOverweight$1,100.00 ➝ $1,050.00+40.33%
8/27/2025Hsbc Global Res
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeModerate SellHold
8/17/2025Daiwa Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperformNeutral$700.00-0.22%
8/17/2025Daiwa America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeStrong-BuyHold
8/14/2025DZ Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeHoldStrong-Buy
8/13/2025Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOverweight$975.00 ➝ $825.00+25.02%
8/13/2025Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetBuy$942.00 ➝ $875.00+35.19%
8/11/2025Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetBuy$1,010.00 ➝ $900.00+40.51%
8/8/2025UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetBuy$1,050.00 ➝ $895.00+42.63%
8/7/2025Leerink Partnrs
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeStrong-BuyHold
8/7/2025Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperformMarket Perform$715.00+11.07%
6/5/2025Erste Group Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuyHold
5/1/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOverweight
4/8/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutralBuy$892.00 ➝ $888.00+20.24%
2/3/2025Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$1,029.00 ➝ $1,038.00+27.51%
1/28/2025Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetBuy$1,250.00 ➝ $1,190.00+47.25%
12/10/2024Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingBuy$997.00+24.17%
11/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Initiated CoverageOutperform$1,000.00+27.23%
11/4/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
10/31/2024Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetOverweight$1,025.00 ➝ $975.00+16.30%
10/17/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$1,100.00+20.04%
9/5/2024Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
8/9/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetOutperform$1,001.00 ➝ $1,101.00+30.36%
6/24/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$994.00 ➝ $1,015.00+12.98%
5/14/2024Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$770.00 ➝ $840.00+11.04%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 06:34 AM ET.


Should I Buy Eli Lilly and Company Stock? LLY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, October 6, 2025. Please send any questions or comments about these Eli Lilly and Company pros and cons to contact@marketbeat.com.

Eli Lilly and Company
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Eli Lilly and Co:

  • The company recently reported strong quarterly earnings, exceeding consensus estimates for both EPS and revenue, indicating robust financial health and growth potential.
  • Eli Lilly and Co has a high return on equity, showcasing effective management and profitability, which can be attractive to investors looking for strong performance.
  • The current stock price is around $825, reflecting a significant increase from its 12-month low, suggesting positive market sentiment and potential for further appreciation.
  • With a consensus rating of "Moderate Buy" from analysts, there is a general optimism about the company's future performance, which can encourage investment.
  • The company has a solid market capitalization, indicating stability and the ability to invest in research and development for new pharmaceuticals.

Eli Lilly and Company
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Eli Lilly and Co for these reasons:

  • The stock has a relatively high PE ratio, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
  • Recent downgrades from analysts, including a shift from "strong-buy" to "hold," may signal concerns about future growth prospects.
  • The company has a high debt-to-equity ratio, which could pose risks in terms of financial stability and flexibility, especially in a rising interest rate environment.
  • Insider transactions show that while some executives are buying shares, the overall insider ownership is low, which may raise questions about their confidence in the company's future.
  • Market volatility and economic uncertainties could impact the pharmaceutical sector, affecting Eli Lilly and Co's stock performance.

LLY Forecast - Frequently Asked Questions

According to the research reports of 25 Wall Street equities research analysts, the average twelve-month stock price forecast for Eli Lilly and Company is $938.94, with a high forecast of $1,190.00 and a low forecast of $700.00.

25 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and Company in the last twelve months. There are currently 10 hold ratings, 14 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LLY shares.

According to analysts, Eli Lilly and Company's stock has a predicted upside of 11.21% based on their 12-month stock forecasts.

Over the previous 90 days, Eli Lilly and Company's stock had 3 upgrades and 3 downgrades by analysts.

Analysts like Eli Lilly and Company more than other "medical" companies. The consensus rating for Eli Lilly and Company is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how LLY compares to other companies.


This page (NYSE:LLY) was last updated on 10/8/2025 by MarketBeat.com Staff
From Our Partners